Microsoft, weight loss drug sales, and GSK profits surge

Business

In today’s episode, Ian King speaks with Dan Ives – managing director of the brokerage and advisory firm Wedbush Securities – to discuss Microsoft’s revenues and AI.

Ian Johnston, global pharmaceutical correspondent at the Financial Times, discusses sales of popular weight loss drug ‘Wegvoy’, made by Novo Nordisk – as they say their sales almost quadrupled last year.

And, Ian discusses GSK’s operating profit of £8.8bn for 2023 with strong selling medicines including its HIV and shingles medication.

Articles You May Like

Johnson over Bears’ potential: ‘It’s about action’
Biden will now be a ‘lame duck’ president after TV address reminds Democrats why they changed top of ticket
Murray to retire as he says Olympics are his ‘last ever tennis tournament’
Tesla obtains exemption for Cybertruck from Transport Canada ahead of launch
Bangladesh’s top court scales back jobs quota after more than 100 killed in protests